PDH30: ROLE OF HRQL EVALUATION IN THE DRUG REGULATORY PROCESS: PRELIMINARY RESULTS FROM A EUROPEAN REGULATORY SURVEY  by Acquadro, C
164 Abstracts
PDH28
A DRUG COST MODEL FOR A CAPITATED 
PATIENT POPULATION WITHIN AN 
INTEGRATED HEALTH CARE SYSTEM
Patel RP, Petitta A, Andrews MJ
Henry Ford Health System, Bingham Farms, MI, USA
OBJECTIVE: To identify the factors predicting outpa-
tient drug costs and quantify their magnitude. METH-
ODS: Data were collected for the capitated patient popu-
lations enrolled at the sixty-one ambulatory internal
medicine, pediatric medicine, and family practice clinics
located within the 21 outpatient sites of the Henry Ford
Health System. Medicare risk patients were excluded
since these programs often have limited prescription ben-
efits. The data included drug costs, diagnoses, and demo-
graphic information. Many factors including age, gender,
HIV, diabetes, transplant, congestive heart failure, coro-
nary artery disease, and percent Medicaid were identified
as possible contributors towards these per member per
month (PMPM) drug costs. The data for each of these
factors were input into a multivariate linear regression
model as the independent variables, while prescription
PMPM costs were designated as the dependent variable.
The regression model was created using the SPSS soft-
ware program. RESULTS: Five factors found to be statis-
tically significant predictors of PMPM drug cost were the
percentage of patients: between ages 40 to 64 (P 
0.000); with diabetes (P  0.044); receiving HIV drug
treatment (P  0.034); who were female (P  0.025);
with a transplant diagnosis (P  0.000). The best-fit
model was $PMPM  [(41.88  % 40–64 years) 
(71.77  % of diabetic patients)  (775.6  % on HIV
drugs)  (2299  % of transplant patients)  (11.30 
% of female patients)]  0.0233 (adjusted r2  0.957).
Age of 65 or greater was not a significant predicator be-
cause Medicare enrollees were not included. CONCLU-
SION: Age of 40 to 64, diabetes, HIV, transplant, and fe-
male gender are the five factors strongly predictive of
drug costs in this capitated population. This model can
be used to risk adjust and predict the pharmaceutical
budgets of the various sites within an integrated health
system.
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FACTORS AFFECTING ASTHMATIC, DIABETIC, 
AND HYPERTENSIVE PATIENT SELF-REPORTED 
COMPLIANCE IN A PHARMACEUTICAL CARE 
DEMONSTRATION PROJECT
Chaikledkaew U, Kamath T, Johnson KA
Department of Pharmaceutical Economics and Policy, School 
of Pharmacy, University of Southern California, Los Angeles, 
CA, USA
Compliance with medication is defined as the extent to
which a patient’s medication taking behavior conforms
to medical or health professional’s advice. Noncompli-
ance leads to preventable adverse drug reactions, unnec-
essary hospitalizations and increase in subsequent health-
care costs. OBJECTIVES: To investigate factors that
influence patient compliance in a sample of elderly popu-
lation suffering from asthma, diabetes, and/or hyperten-
sion. METHODS: Data on 201 patients with asthma, di-
abetes, and/or hypertension were obtained from “Pharmacist
service questionnaire” surveys. The compliance was as-
sessed by using questions based on a validated Morisky
score. Patient compliance was modeled as a function of
four groups of variables (i.e., patient demographic char-
acteristics, health behavior, quality of life, and patient
satisfaction in phamacy service). Correlation between
these variables and patient compliance was estimated by
ordinary least square (OLS) and logistic regression meth-
ods. RESULTS: Based on the OLS analysis, the following
variables had a significant impact on patient compliance:
age (P  0.04), baseline compliance (P  0.001), and pa-
tient satisfaction with pharmacy service (P  0.03). Lo-
gistic regression analysis showed that age (odds ratio,
OR  1.05), high school graduation (OR  0.11), and
baseline compliance (OR  7.12) had a significant influ-
ence on patient compliance. CONCLUSION: The find-
ings suggest that older patients, patients with less than
high school education, and patients with high satisfaction
in pharmacy service are more likely to be compliant. Pa-
tients self-reporting good compliance with previous med-
ications are more likely to comply. These factors should
be taken into account to target interventions at noncom-
pliant patients.
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ROLE OF HRQL EVALUATION IN THE DRUG 
REGULATORY PROCESS: PRELIMINARY 
RESULTS FROM A EUROPEAN 
REGULATORY SURVEY
Acquadro C
Mapi Research Institute, Lyon, France, for the European 
Regulatory Issues on QoL Assessment (ERIQA) Group
BACKGROUND: The ERIQA Group was created, with
the following mission statement: “establishing principles
and practices for the integration of Health-related Qual-
ity of Life (HRQL) outcomes in the drug regulatory pro-
cess”. As part of its activities of year 1999, the ERIQA
Group surveyed European Regulatory Authorities (EMEA
and country-specific agencies). OBJECTIVES: To clarify
in more detail the role of HRQL in the European regula-
tory process of pharmaceutical products (registration, re-
imbursement and promotion), i.e., to better understand
how HRQL evaluation is considered by regulators; and
their potential needs with regards to HRQL issues.
METHODS: Three questionnaires were developed, one
for each regulatory area, and sent to 60 representatives of
regulatory agencies in the 15 European countries repre-
sented at the EMEA, among them the 30 CPMP mem-
bers. Questionnaires were divided in three informative
parts: generic/ID; specific, and perspectives for the future.
They covered the first 6 months of year 1999. PRELIMI-
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NARY RESULTS: Information was retrieved from 6
countries: Belgium, Denmark, Finland, France, Germany,
Italy. Representatives from 5 countries (Austria, Ireland,
Spain, The Netherlands, UK) expressed their will of not
providing data. Information is still expected from 4 coun-
tries (Greece, Luxembourg, Portugal, Sweden). Most of
the respondents deplored the poor quality of HRQL data
provided, leading them to discard HRQL evaluation in
the regulatory process. Nevertheless, 91% expressed
their need for guidance in HRQL issues, and 63% their
need for training. CONCLUSION: HRQL evaluation
currently plays no determining role in the European drug
regulatory process. More efforts should be developed to
improve the quality of HRQL studies, and therefore con-
vince regulators that HRQL is a credible criterion of
evaluation of medicines.
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HEALTH RELATED QUALITY OF LIFE AND 
REGULATORY ISSUES: COMPARISON OF US 
AND EUROPEAN INITIATIVES
Marquis P1, Abetz L2, Acquadro C3, for the ERIQA Group
1Mapi Values, Lyon, France; 2Mapi Values, Bollington, UK; 3Mapi 
Research Institute, Lyon, France
A number of groups have considered the use of HRQL
assessments for regulatory purposes. The Pharmaceutical
Research and Manufacturers of America (PhRMA) Health
Outcomes Working Group (HOWG), the International
Society for Pharmacoeconomics and Outcomes Research
(ISPOR), and the International Society for Quality of Life
Research (ISOQOL) have considered the US regulatory
situation, and the European Regulatory Issues on Quality
of Life Assessment (ERIQA) group has looked at the cur-
rent status in Europe. These groups have each produced
documents intended for the regulatory authorities, sum-
marising the state of the art of HRQL evaluation in clini-
cal trials. A comparison of these documents has been un-
dertaken, with the aim of highlighting areas of agreement
and dissent and identifying those issues in need of further
consideration. Seven topics have been considered when
reviewing the documents: concepts (definitions and ter-
minology), rationale for HRQL evaluation, instruments,
study design, data analysis, interpretation and conditions
for HRQL claims. Within each topic, issues addressed by
all or only some of the initiatives have been identified,
and recommendations made (if any) have been com-
pared. For a number of issues, recommendations are con-
sistent between the various initiatives. For example, all
recommend that it should be a requirement to justify the
choice of an HRQL questionnaire, and to provide details
of the psychometric properties of instruments used. By
contrast, there is a lack of consensus concerning the num-
ber of trials required to support an HRQL promotional
claim. This work indicates that collaboration between
the various groups is essential to reach an optimal degree
of agreement. It is proposed that a conference be organ-
ised in the final quarter of the year 2000 involving dele-
gates from each initiative with the objective of achieving
harmonisation of recommendations to be made to regu-
latory authorities.
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COST IMPACT OF A PRESCRIPTION BENEFIT 
CHANGE IN A MEDICARE MANAGED 
CARE PLAN
Balkrishnan R1, Byerly WG2
1Wake Forest University, School of Medicine, Winston-Salem, 
NC, USA; 2Wake Forest University, Baptist Medical Center, 
Winston-Salem, NC, USA
Studies have individually examined the impact of copay-
ment level changes and prescription expenditure caps on
total health care service utilization and costs in managed
care plans. OBJECTIVE: We examined the impact of a
change in prescription benefit that included both changes
in copayment levels as well as prescription reimburse-
ment limits on health care service utilization and charges.
The change in prescription benefit included a change
from $200 quarterly reimbursement cap to unlimited ge-
neric coverage and $25 monthly cap in brand-name drug
reimbursements with a decrease in copayment for generic
drugs from $7 to $5 per prescription. METHODS: A co-
hort of 3116 older adults continuously enrolled in a
Medicare managed care plan from January 1998 were
followed up for health care service utilization and charges
before and after introduction of the change effective Jan-
uary 1999. Multiple regression analyses were conducted
to examine the impact of the prescription coverage
change, after adjusting for demographic, clinical, and
medication-related variables. RESULTS: Analysis of pa-
tient data in the first six months of the two years showed
that the prescription benefit change was associated with a
33% decrease in prescription charges, and a 9% decrease
in health care service charges. There was an increase of
5% in the health care service utilization and 9% increase
in the number of prescriptions filled, but the 10% in-
crease in the generic prescriptions, and small reduction in
length of hospital stay accounted for the overall reduc-
tion in total health care charges. CONCLUSION: The
change in prescription benefit with a lower brand-name
cap and lower generic copayment increased the generic
drug utilization and decreased total health care charges.
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EVALUATION AND TREATMENT OF SHORT 
STATURE: NATIONAL COOPERATIVE GROWTH 
STUDY (NCGS) EXPERIENCE
Blethen SL
Genentech, Inc., South San Francisco, CA, USA
OBJECTIVE: The National Cooperative Growth Study
(NCGS) is an observational registry that monitors out-
comes in children treated with growth hormone (GH).
METHODS: As of June 30, 1999, data had been col-
